Unlock instant, AI-driven research and patent intelligence for your innovation.

HIV-1 resistance strain and use thereof

A technology for drug resistance and virus strains, applied in the direction of viruses/phages, medical materials derived from viruses/phages, microorganisms, etc., can solve the problems of lack of systematic research and constraints on HIV drug resistance

Inactive Publication Date: 2007-10-31
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is still a lack of systematic research on HIV drug resistance in my country, and so far there is no standard drug-resistant strain used in the evaluation of new AIDS drugs and HIV-1 drug resistance research
At the same time, in the HIV-1 drug resistance research that has just started in my country, it is also greatly restricted because there is no standard drug-resistant strain of HIV-1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1、3

[0008] Embodiment 1, the cultivation and screening of 3TC HIV-1 drug-resistant strains

[0009] 1. Experimental materials

[0010] 1. Virus: HIV-1 CNHN24 strain, which was isolated from peripheral blood lymphocytes of AIDS patients in Henan, China in 2002, Genbank registration number AY180905, genotype is B' subtype, and the band type detected by HIV antibody immunoblotting is gp160, gp120, p66, p55, gp41, p24, p17.

[0011] 2. Cells: MT4 cells, cultured and subcultured with RPMI1640 medium containing 10% calf serum.

[0012] 3. Screening drugs: 3TC drugs are Heprudine Lamivudine Tablets produced by GlaxoSmithKline Pharmaceuticals, each containing 100 mg of Lamivudine. Dissolve 100mg of 3TC in 50ml of RPMI1640 culture medium, and centrifugally filter to obtain 8.7mM 3TC solution, which should be diluted to the desired concentration before use.

[0013] 4. Cell culture medium: RPMI1640 cell culture medium containing 10% calf serum.

[0014] 2. Cultivation of 3TC HIV-1 drug-...

Embodiment 2

[0032] Embodiment 2, application of 3TC HIV-1 drug-resistant strains to screen anti-HIV drugs

[0033] 1. Experimental materials

[0034] 1. The test drug DCP 961 ( *J. Med. Chem. 2000, 43, 2019-2030. Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors. Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers, et al)

[0035] Physical and chemical properties: white powder

[0036] 2. Positive control drug AZT

[0037] Provider: SIGMA, batch number: 021033

[0038] 3. Cells

[0039] MT-4, preserved by the Army AIDS Testing Center of the Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, was cultured and subcultured with RPMI 1640 medium containing 10% fetal bovine serum.

[0040] 4. Viruses

Embodiment 1

[0041] The 3TC HIV-1 drug-resistant strain obtained in Example 1.

[0042] 5. Basic conditions of the experiment

[0043] The anti-HIV-1 activity experiment was carried out in a biosafety level 3 laboratory.

[0044] 2. Drug screening process

[0045] 1. The infectivity titer (TCID) of virus to MT-4 cells was determined by CPE method 50 )

[0046] MT-4 cells were seeded in a 96-well plate, 100 μl per well, containing 2.5×10 cells 4 cells / ml, the virus stock solution was diluted 10 times with the culture medium, and a total of 9 concentrations were added to the cell wells, 4 wells per concentration, 37 ° C, 5% CO 2 Incubator cultivation. Cytopathic changes (CPE) were observed daily with an inverted microscope. Cytopathic changes below 25% are +, 26-50% lesions are ++, 51-75% lesions are +++, and 76-100% lesions are ++++. Cytopathic extent (CPE) was recorded. The infectious titer (TCID) of the virus was calculated by the Reed-Muench method 50 ).

[0047] 2. MTT method ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

HIV-1 drug-resistant strain and its use are disclosed. The strain is 3TC HIV-1 drug-resistant strain CGMCC No 1140, median inhibiting concentration(IC50) is >2048muM for 3TC and it has generation stability. It can be used for anti-AIDS medicine screen.

Description

technical field [0001] The invention relates to HIV-1 drug-resistant strains and applications thereof. Background technique [0002] At present, there is a peak of AIDS incidence in our country. By the end of September 2003, there are as many as 840,000 living HIV-infected people in our country. Since 2002, four domestic anti-HIV drugs have been launched on the market, which has reduced the annual treatment cost of AIDS patients from the original 40,000 yuan to the current 3,500 yuan. The discovery of new anti-AIDS drugs is undoubtedly the benefit of the majority of AIDS patients, but at the same time there has also been a serious problem of drug resistance of the HIV virus. [0003] According to the requirements of the Drug Evaluation Center of the State Food and Drug Administration, when evaluating the efficacy of anti-AIDS drugs, three viruses (experimental strains, clinical isolates, and drug-resistant strains) must be used for in vitro experiments. There is still a la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N7/01A61K35/76C12R1/93
Inventor 李敬云李珏鲍作义刘思扬庄道民李韩平刘永健李林杨坤
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI